CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 23 enrolled
Drug / intervention
chenodeoxycholic aciddrug
Likely dose
Chenodeoxycholic acid 1250 mg given with a study mealAI-extracted
Key inclusion· 1
  • ✓Planned elective cholecystectomy
Key exclusion· 9
  • ✕Prior small bowel resection
  • ✕Prior right-sided hemicolectomy
  • ✕Chronic diarrheal disease (celiac disease, lactose malabsorption, inflammatory bowel disease, microscopic colitis)
  • ✕Pregnancy or wish to become pregnant within 3 months

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03168555
NCT03168555Phase 4Completed
CompareCT.gov

Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy

Zealand University Hospital·interventional·Posted May 30, 2017·Updated May 19, 2022

In Brief

A Phase 4 clinical trial evaluating chenodeoxycholic acid for Bile Acid Malabsorption and Cholelithiasis. Completed, enrolled 23 participants across 1 site.

Detailed Summary

Investigate serial plasma samples of fibroblast growth factor 19 (FGF19) after oral stimulation with chenodeoxycholic acid in the same subjects before and after elective cholecystectomy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBile Acid Malabsorption, Cholelithiasis
CountriesDenmark
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedMay 30, 2017
Enrollment StartJun 22, 2017
Primary CompletionMay 15, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.1 years ago

Interventions

chenodeoxycholic aciddrug

1250 mg CDCA is given with a study meal